In Reply: Dr Kavsak makes several important points regarding our studies on the potential utility of highly sensitive cTnT assays for risk stratification of the general population. First, he notes that no standard has been set for how values of cTnT measured with these assays should be reported and highlights the potential for transcription or reporting errors when very low values are reported as ng/mL, with multiple decimal places in the value. Indeed, he has detected just such an error in our article. We acknowledge errors in reporting of the highest category of values in Tables 2 and 3 and Figure 1, which were reported as 0.0014 ng/mL or greater, when the correct value is 0.014 ng/mL or greater. A published correction appears in this issue.
de Lemos JA, Christenson RH, deFilippi CR. Highly Sensitive Cardiac Troponin T Assay, Cardiac Disease, and Mortality Risk—Reply. JAMA. 2011;305(12):1196-1197. doi:10.1001/jama.2011.346